Evidence map›Paper›PMID 33416200›Full record

Trial reportDiabetes, obesity & metabolism2021

A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.

Masaru Kitazawa, Takashi Katagiri, Hiromi Suzuki, Satoshi Matsunaga, Mayuko H Yamada, Tomoo Ikarashi, Masahiko Yamamoto, Kazuo Furukawa, Midori Iwanaga, Mariko Hatta and 4 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 4 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Comparative Safety of SGLT2 Versus DPP4 Inhibitors in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Masaru KitazawaDepartment of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Takashi KatagiriKashiwazaki General Hospital and Medical Center, Kashiwazaki, Japan.
Hiromi SuzukiNiigata Prefectural Shibata Hospital, Shibata, Japan.
Satoshi MatsunagaNiigata Prefectural Chuo Hospital, Joetsu, Japan.
Mayuko H YamadaDepartment of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Tomoo IkarashiNiigata Medical Center, Niigata, Japan.
Masahiko YamamotoDepartment of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Kazuo FurukawaNagaoka Red Cross Hospital, Nagaoka, Japan.
Midori IwanagaDepartment of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Mariko HattaDepartment of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Kazuya FujiharaDepartment of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Takaho YamadaDepartment of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Shiro TanakaDepartment of Clinical Biostatistics/Clinical Biostatistics Course, Graduate School of Medicine Kyoto University, Kyoto, Japan.
Hirohito SoneDepartment of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Niigata University · JPKyoto University · JPNagaoka Red Cross Hospital · JPNiigata Prefectural Central Hospital · JPNiigata Prefectural Kashiwazaki Technical High School · JPNiigata Prefectural Shibata Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo compare the long-term efficacy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors as second-line drugs after metformin for patients not at high risk of atherosclerotic cardiovascular disease (ASCVD). MATERIALS AND

methodsIn a 52-week randomized open-label trial, we compared ipragliflozin and sitagliptin in Japanese patients diagnosed with type 2 diabetes, without prior ASCVD and treated with metformin. The primary endpoint was a glycated haemoglobin (HbA1c) reduction of ≥0.5% (5.5 mmol/mol) without weight gain at 52 weeks.

resultsOf a total of 111 patients (mean age 59.2 years, mean body mass index [BMI] 26.6 kg/m

conclusionThe HbA1c-lowering effect at 24 weeks was greater with sitagliptin than with ipragliflozin, but with no difference in efficacy related to HbA1c and body weight at 52 weeks. However, some ASCVD risk factors improved with ipragliflozin.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsMetforminDouble-Blind MethodDrug Therapy, CombinationFemaleGlucosidesGlycated HemoglobinHumansHypoglycemic AgentsMaleMiddle AgedSitagliptin PhosphateThiophenesTreatment OutcomeDipeptidyl-Peptidase IV InhibitorsGlucosidesGlycated HemoglobinHypoglycemic AgentsipragliflozinMetforminSitagliptin PhosphateThiophenesclinical trialDPP-4 inhibitorglycaemic controlrandomized trialSGLT2 inhibitorsitagliptin

Identifiers

PMID33416200
PMCPMC7898334
OpenAlexW3120294371

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.